This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (10)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Lipids and Lipid Disorders  • Drug Therapy, Other  • Diabetes Mellitus  • Alert me on articles by topic  Social Bookmarking   What's this?

Glucose and Lipid Effects

Harold E. Bays, MD; Ronald B. Goldberg, MD; Kenneth E. Truitt, MD; Michael R. Jones, PhD

Arch Intern Med. 2008;168(18):1975-1983.

Background  Bile acid sequestrants are a well-accepted class of cholesterol-lowering drugs. Over the last decade, small studies have indicated that these agents may also lower glucose levels in patients with type 2 diabetes mellitus (T2DM).

Methods  This 26-week, randomized, double-blind, placebo-controlled, parallel-group study was conducted between August 2004 and July 2006 at 54 sites in the United States and 2 in Mexico to determine the effects of colesevelam hydrochloride, a bile acid sequestrant, in patients with inadequately controlled T2DM (hemoglobin A_1c [HbA_1c] level, 7.5%-9.5% [baseline HbA_1c level, 8.1%]), who were receiving metformin monotherapy or metformin combined with additional oral anti–diabetes mellitus drugs. In total, 316 subjects were randomized (159 to colesevelam hydrochloride, 3.75 g/d, and 157 to matching placebo). The primary efficacy parameter was mean placebo-corrected change in HbA_1c level from baseline to week 26 (analysis was on an intent-to-treat population using a last-observation-carried-forward approach).

Results  Colesevelam lowered the mean HbA_1c level compared with placebo at week 26 (–0.54%; P < .001). Similar results were observed in the metformin monotherapy (–0.47%; P = .002) and combination therapy cohorts (–0.62%; P < .001). In addition, colesevelam significantly (1) lowered fasting plasma glucose (–13.9 mg/dL P = .01), fructosamine (–23.2 µmol/L; P < .001), total cholesterol (TC) (–7.2%; P < .001), low-density lipoprotein cholesterol (LDL-C) (–15.9%; P < .001), apolipoprotein B (–7.9%; P < .001), non–high-density lipoprotein cholesterol (HDL-C) (–10.3%; P < .001), and high-sensitivity C-reactive protein (–14.4%; P = .02) levels and (2) improved other measures of glycemic response, as well as TC/HDL-C, LDL-C/HDL-C, non–HDL-C/HDL-C, and apolipoprotein B/apolipoprotein A-I ratios (P < .003 for all). Triglyceride, HDL-C, and apolipoprotein A-I levels were not statistically significantly increased.

Conclusion  Colesevelam improves glycemic and lipid parameters in patients with T2DM inadequately controlled with metformin-based therapy.

Trial Registration  clinicaltrials.gov Identifier: NCT00147719

Author Affiliations: Louisville Metabolic and Atherosclerosis Research Center Inc, Louisville, Kentucky (Dr Bays); Lipid Disorders Clinic, Division of Endocrinology, Diabetes, and Metabolism, and the Diabetes Research Institute, Leonard M. Miller School of Medicine, University of Miami, Miami, Florida (Dr Goldberg); Daiichi Sankyo Pharma Development, Edison, New Jersey (Dr Truitt); and Daiichi Sankyo, Inc, Parsippany, New Jersey (Dr Jones).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Bile Acids and Metabolic Regulation: Mechanisms and clinical responses to bile acid sequestration
Staels and Fonseca
Diabetes Care 2009;32:S237-S245.
FULL TEXT  

Quantitative Structure-Property Relationships Modeling to Predict In Vitro and In Vivo Binding of Drugs to the Bile Sequestrant, Colesevelam (Welchol)
Walker et al.
J Clin Pharmacol 2009;49:1185-1195.
ABSTRACT | FULL TEXT